MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Ardelyx Inc

Closed

SectorHealthcare

5.01 3.51

Overview

Share price change

24h

Current

Min

4.79

Max

5.02

Key metrics

By Trading Economics

Income

5.5M

4.6M

Sales

18M

116M

EPS

0.02

Profit margin

4

Employees

395

EBITDA

6M

11M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+133.2% upside

Dividends

By Dow Jones

Next Earnings

1 maj 2025

Market Stats

By TradingEconomics

Market Cap

-122M

1.1B

Previous open

1.5

Previous close

5.01

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

Ardelyx Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

22 sty 2025, 23:40 UTC

Major Market Movers

Ardelyx Shares Rise as Chairman Mott Increases Stake in Company

Peer Comparison

Price change

Ardelyx Inc Forecast

Price Target

By TipRanks

133.2% upside

12 Months Forecast

Average 11.31 USD  133.2%

High 15 USD

Low 5.5 USD

Based on 8 Wall Street analysts offering 12 month price targets forArdelyx Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

6

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

4.815 / 4.84Support & Resistance

Short Term

Very Strong Bullish Evidence

Intermediate Term

Very Strong Bearish Evidence

Long Term

Neutral Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.